{
  "company_id": "jnj",
  "company_name": "Johnson & Johnson",
  "generated_at": "2026-02-04T21:41:53Z",
  "kpis": {
    "assets_total": 44,
    "assets_with_trials": 20,
    "trials_total": 263
  },
  "top_assets": [
    {
      "asset_id": 64,
      "asset_name": "Azacitidine",
      "highest_stage": "Registration",
      "linked_trials_count": 5,
      "indications": [
        {
          "indication": "Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 45,
      "asset_name": "ypertension75mg",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        },
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        },
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 69,
      "asset_name": "(PROTOSTAR)",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Arthritis Hemolytic Anemia (ENERGY) Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 14,
      "asset_name": "(ORIGAMI-2)",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 23,
      "asset_name": "(MajesTEC-4)",
      "highest_stage": "Registration",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 25,
      "asset_name": "TREMFYA",
      "highest_stage": "Phase 3",
      "linked_trials_count": 29,
      "indications": [
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 10,
      "asset_name": "ERLEADA",
      "highest_stage": "Phase 3",
      "linked_trials_count": 24,
      "indications": [
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 57,
      "asset_name": "nipocalimab",
      "highest_stage": "Phase 3",
      "linked_trials_count": 11,
      "indications": [
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 12,
      "asset_name": "TALVEY + TECVAYLI",
      "highest_stage": "Phase 3",
      "linked_trials_count": 7,
      "indications": [
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory (MonumenTAL-6)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 26,
      "asset_name": "icotrokinra",
      "highest_stage": "Phase 3",
      "linked_trials_count": 4,
      "indications": [
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease (ICONIC-CD)",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 19,
      "asset_name": "bleximenib",
      "highest_stage": "Phase 3",
      "linked_trials_count": 4,
      "indications": [
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 5,
      "asset_name": "RYBREVANT",
      "highest_stage": "Phase 3",
      "linked_trials_count": 4,
      "indications": [
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 37,
      "asset_name": "SPRAVATO",
      "highest_stage": "Phase 3",
      "linked_trials_count": 3,
      "indications": [
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 22,
      "asset_name": "JNJ-7446",
      "highest_stage": "Phase 3",
      "linked_trials_count": 2,
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 1,
      "asset_name": "INLEXZO (gemcitabine",
      "highest_stage": "Phase 3",
      "linked_trials_count": 2,
      "indications": [
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Non Muscle Invasive (SunRISe-3)",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 43,
      "asset_name": "SIRTURO",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 62,
      "asset_name": "Leprosy",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        },
        {
          "indication": "under review by regulatory bodies.",
          "stage": "Phase 3",
          "therapeutic_area": null
        }
      ]
    },
    {
      "asset_id": 28,
      "asset_name": "JNJ-4804 Co-antibody",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology"
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology"
        }
      ]
    },
    {
      "asset_id": 21,
      "asset_name": "JNJ-4681",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 66,
      "asset_name": "JNJ-3413",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Lymphoma",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 20,
      "asset_name": "JNJ-2175",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 60,
      "asset_name": "JNJ-1887 sCD59",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 33,
      "asset_name": "ITI-1284",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience"
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience"
        }
      ]
    },
    {
      "asset_id": 9,
      "asset_name": "Bleximenib",
      "highest_stage": "Phase 3",
      "linked_trials_count": 0,
      "indications": [
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology"
        }
      ]
    },
    {
      "asset_id": 63,
      "asset_name": "(amivantamab)",
      "highest_stage": "Phase 2",
      "linked_trials_count": 27,
      "indications": [
        {
          "indication": "Cancer (ORIGAMI-5)",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology"
        }
      ]
    }
  ],
  "recent_changes": [
    {
      "event_type": "trials_ingested",
      "created_at": "2026-02-04 21:41:46.960788",
      "occurred_at": "2026-02-04 21:41:46.960788",
      "payload": {
        "trials_seen": 257,
        "inserted": 3,
        "updated": 254,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:45.615989",
      "occurred_at": "2026-02-04 21:41:45.615989",
      "payload": {
        "nct_id": "NCT05567185",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:45.593632",
      "occurred_at": "2026-02-04 21:41:45.593632",
      "payload": {
        "nct_id": "NCT06919965",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:45.579091",
      "occurred_at": "2026-02-04 21:41:45.579091",
      "payload": {
        "nct_id": "NCT06319820",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 21:41:45.165853",
      "occurred_at": "2026-02-04 21:41:45.165853",
      "payload": {
        "nct_id": "NCT07194070",
        "title": "Global Prospective Hemolytic Disease of the Fetus and Newborn Registry"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:33.854107",
      "occurred_at": "2026-02-04 21:41:33.854107",
      "payload": {
        "nct_id": "NCT04150887",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 21:41:33.844218",
      "occurred_at": "2026-02-04 21:41:33.844218",
      "payload": {
        "nct_id": "NCT04150887",
        "title": "An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:33.385659",
      "occurred_at": "2026-02-04 21:41:33.385659",
      "payload": {
        "nct_id": "NCT04023526",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_added",
      "created_at": "2026-02-04 21:41:33.375138",
      "occurred_at": "2026-02-04 21:41:33.375138",
      "payload": {
        "nct_id": "NCT04023526",
        "title": "A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy"
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:32.442221",
      "occurred_at": "2026-02-04 21:41:32.442221",
      "payload": {
        "nct_id": "NCT04883619",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:32.428573",
      "occurred_at": "2026-02-04 21:41:32.428573",
      "payload": {
        "nct_id": "NCT06533098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:32.415105",
      "occurred_at": "2026-02-04 21:41:32.415105",
      "payload": {
        "nct_id": "NCT06449651",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:32.402416",
      "occurred_at": "2026-02-04 21:41:32.402416",
      "payload": {
        "nct_id": "NCT05379634",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:32.389244",
      "occurred_at": "2026-02-04 21:41:32.389244",
      "payload": {
        "nct_id": "NCT05327114",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:32.375434",
      "occurred_at": "2026-02-04 21:41:32.375434",
      "payload": {
        "nct_id": "NCT04119050",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:31.300254",
      "occurred_at": "2026-02-04 21:41:31.300254",
      "payload": {
        "nct_id": "NCT06878404",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:31.284795",
      "occurred_at": "2026-02-04 21:41:31.284795",
      "payload": {
        "nct_id": "NCT06807424",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.987138",
      "occurred_at": "2026-02-04 21:41:29.987138",
      "payload": {
        "nct_id": "NCT03767075",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.973311",
      "occurred_at": "2026-02-04 21:41:29.973311",
      "payload": {
        "nct_id": "NCT06816992",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.960358",
      "occurred_at": "2026-02-04 21:41:29.960358",
      "payload": {
        "nct_id": "NCT06632236",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.948134",
      "occurred_at": "2026-02-04 21:41:29.948134",
      "payload": {
        "nct_id": "NCT07062354",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.935268",
      "occurred_at": "2026-02-04 21:41:29.935268",
      "payload": {
        "nct_id": "NCT05117931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.923739",
      "occurred_at": "2026-02-04 21:41:29.923739",
      "payload": {
        "nct_id": "NCT05299125",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.910895",
      "occurred_at": "2026-02-04 21:41:29.910895",
      "payload": {
        "nct_id": "NCT04988295",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.886495",
      "occurred_at": "2026-02-04 21:41:29.886495",
      "payload": {
        "nct_id": "NCT04077463",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.862291",
      "occurred_at": "2026-02-04 21:41:29.862291",
      "payload": {
        "nct_id": "NCT05845671",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.847247",
      "occurred_at": "2026-02-04 21:41:29.847247",
      "payload": {
        "nct_id": "NCT06385080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.832677",
      "occurred_at": "2026-02-04 21:41:29.832677",
      "payload": {
        "nct_id": "NCT06667076",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.815348",
      "occurred_at": "2026-02-04 21:41:29.815348",
      "payload": {
        "nct_id": "NCT06750094",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.797506",
      "occurred_at": "2026-02-04 21:41:29.797506",
      "payload": {
        "nct_id": "NCT06120140",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.778102",
      "occurred_at": "2026-02-04 21:41:29.778102",
      "payload": {
        "nct_id": "NCT06532032",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.755952",
      "occurred_at": "2026-02-04 21:41:29.755952",
      "payload": {
        "nct_id": "NCT05498428",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.739657",
      "occurred_at": "2026-02-04 21:41:29.739657",
      "payload": {
        "nct_id": "NCT06662786",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.722081",
      "occurred_at": "2026-02-04 21:41:29.722081",
      "payload": {
        "nct_id": "NCT05488314",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.708140",
      "occurred_at": "2026-02-04 21:41:29.708140",
      "payload": {
        "nct_id": "NCT02609776",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.692778",
      "occurred_at": "2026-02-04 21:41:29.692778",
      "payload": {
        "nct_id": "NCT05908734",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.678799",
      "occurred_at": "2026-02-04 21:41:29.678799",
      "payload": {
        "nct_id": "NCT05601973",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.662634",
      "occurred_at": "2026-02-04 21:41:29.662634",
      "payload": {
        "nct_id": "NCT05388669",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.641832",
      "occurred_at": "2026-02-04 21:41:29.641832",
      "payload": {
        "nct_id": "NCT04487080",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.615862",
      "occurred_at": "2026-02-04 21:41:29.615862",
      "payload": {
        "nct_id": "NCT05663866",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:29.176436",
      "occurred_at": "2026-02-04 21:41:29.176436",
      "payload": {
        "nct_id": "NCT06649695",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:28.732622",
      "occurred_at": "2026-02-04 21:41:28.732622",
      "payload": {
        "nct_id": "NCT05421663",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:26.121969",
      "occurred_at": "2026-02-04 21:41:26.121969",
      "payload": {
        "nct_id": "NCT06852222",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:26.105114",
      "occurred_at": "2026-02-04 21:41:26.105114",
      "payload": {
        "nct_id": "NCT04811560",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:26.077140",
      "occurred_at": "2026-02-04 21:41:26.077140",
      "payload": {
        "nct_id": "NCT05453903",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:26.062283",
      "occurred_at": "2026-02-04 21:41:26.062283",
      "payload": {
        "nct_id": "NCT07295951",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:25.695851",
      "occurred_at": "2026-02-04 21:41:25.695851",
      "payload": {
        "nct_id": "NCT07164443",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:25.680165",
      "occurred_at": "2026-02-04 21:41:25.680165",
      "payload": {
        "nct_id": "NCT07082920",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:25.665566",
      "occurred_at": "2026-02-04 21:41:25.665566",
      "payload": {
        "nct_id": "NCT07319871",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:25.653654",
      "occurred_at": "2026-02-04 21:41:25.653654",
      "payload": {
        "nct_id": "NCT06095089",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:25.640863",
      "occurred_at": "2026-02-04 21:41:25.640863",
      "payload": {
        "nct_id": "NCT07225946",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:23.853765",
      "occurred_at": "2026-02-04 21:41:23.853765",
      "payload": {
        "nct_id": "NCT07276399",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:23.839715",
      "occurred_at": "2026-02-04 21:41:23.839715",
      "payload": {
        "nct_id": "NCT07227025",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:23.823078",
      "occurred_at": "2026-02-04 21:41:23.823078",
      "payload": {
        "nct_id": "NCT05379595",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:22.049477",
      "occurred_at": "2026-02-04 21:41:22.049477",
      "payload": {
        "nct_id": "NCT05316155",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:14.517725",
      "occurred_at": "2026-02-04 21:41:14.517725",
      "payload": {
        "nct_id": "NCT04538664",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:12.460282",
      "occurred_at": "2026-02-04 21:41:12.460282",
      "payload": {
        "nct_id": "NCT06103760",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:12.073422",
      "occurred_at": "2026-02-04 21:41:12.073422",
      "payload": {
        "nct_id": "NCT07053345",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:08.087615",
      "occurred_at": "2026-02-04 21:41:08.087615",
      "payload": {
        "nct_id": "NCT02925234",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:07.599770",
      "occurred_at": "2026-02-04 21:41:07.599770",
      "payload": {
        "nct_id": "NCT06149910",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:07.552703",
      "occurred_at": "2026-02-04 21:41:07.552703",
      "payload": {
        "nct_id": "NCT06505369",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:07.041975",
      "occurred_at": "2026-02-04 21:41:07.041975",
      "payload": {
        "nct_id": "NCT06100237",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:06.999301",
      "occurred_at": "2026-02-04 21:41:06.999301",
      "payload": {
        "nct_id": "NCT06477783",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:06.985140",
      "occurred_at": "2026-02-04 21:41:06.985140",
      "payload": {
        "nct_id": "NCT06353022",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:06.968677",
      "occurred_at": "2026-02-04 21:41:06.968677",
      "payload": {
        "nct_id": "NCT05849610",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:06.455746",
      "occurred_at": "2026-02-04 21:41:06.455746",
      "payload": {
        "nct_id": "NCT05469893",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:05.919056",
      "occurred_at": "2026-02-04 21:41:05.919056",
      "payload": {
        "nct_id": "NCT07107529",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:05.872273",
      "occurred_at": "2026-02-04 21:41:05.872273",
      "payload": {
        "nct_id": "NCT06993675",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:05.399055",
      "occurred_at": "2026-02-04 21:41:05.399055",
      "payload": {
        "nct_id": "NCT05767359",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:05.364430",
      "occurred_at": "2026-02-04 21:41:05.364430",
      "payload": {
        "nct_id": "NCT05572229",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.849457",
      "occurred_at": "2026-02-04 21:41:04.849457",
      "payload": {
        "nct_id": "NCT07110844",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.816600",
      "occurred_at": "2026-02-04 21:41:04.816600",
      "payload": {
        "nct_id": "NCT07258511",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.251465",
      "occurred_at": "2026-02-04 21:41:04.251465",
      "payload": {
        "nct_id": "NCT05695508",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.216387",
      "occurred_at": "2026-02-04 21:41:04.216387",
      "payload": {
        "nct_id": "NCT05243797",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.197738",
      "occurred_at": "2026-02-04 21:41:04.197738",
      "payload": {
        "nct_id": "NCT07030517",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.180774",
      "occurred_at": "2026-02-04 21:41:04.180774",
      "payload": {
        "nct_id": "NCT05231629",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.129191",
      "occurred_at": "2026-02-04 21:41:04.129191",
      "payload": {
        "nct_id": "NCT07105059",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.091214",
      "occurred_at": "2026-02-04 21:41:04.091214",
      "payload": {
        "nct_id": "NCT04722146",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.064317",
      "occurred_at": "2026-02-04 21:41:04.064317",
      "payload": {
        "nct_id": "NCT03145181",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.046179",
      "occurred_at": "2026-02-04 21:41:04.046179",
      "payload": {
        "nct_id": "NCT05083169",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.029775",
      "occurred_at": "2026-02-04 21:41:04.029775",
      "payload": {
        "nct_id": "NCT05338775",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:04.016144",
      "occurred_at": "2026-02-04 21:41:04.016144",
      "payload": {
        "nct_id": "NCT06577025",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.480267",
      "occurred_at": "2026-02-04 21:41:03.480267",
      "payload": {
        "nct_id": "NCT06550895",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.466522",
      "occurred_at": "2026-02-04 21:41:03.466522",
      "payload": {
        "nct_id": "NCT04586426",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.453034",
      "occurred_at": "2026-02-04 21:41:03.453034",
      "payload": {
        "nct_id": "NCT05552222",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.424174",
      "occurred_at": "2026-02-04 21:41:03.424174",
      "payload": {
        "nct_id": "NCT06425991",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.402321",
      "occurred_at": "2026-02-04 21:41:03.402321",
      "payload": {
        "nct_id": "NCT04696809",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.388003",
      "occurred_at": "2026-02-04 21:41:03.388003",
      "payload": {
        "nct_id": "NCT04108195",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.372843",
      "occurred_at": "2026-02-04 21:41:03.372843",
      "payload": {
        "nct_id": "NCT04133636",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.357515",
      "occurred_at": "2026-02-04 21:41:03.357515",
      "payload": {
        "nct_id": "NCT05572515",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:03.309358",
      "occurred_at": "2026-02-04 21:41:03.309358",
      "payload": {
        "nct_id": "NCT04557098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:02.735869",
      "occurred_at": "2026-02-04 21:41:02.735869",
      "payload": {
        "nct_id": "NCT02354014",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:02.012258",
      "occurred_at": "2026-02-04 21:41:02.012258",
      "payload": {
        "nct_id": "NCT05858632",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:02.000068",
      "occurred_at": "2026-02-04 21:41:02.000068",
      "payload": {
        "nct_id": "NCT04645355",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.987477",
      "occurred_at": "2026-02-04 21:41:01.987477",
      "payload": {
        "nct_id": "NCT06563323",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.974465",
      "occurred_at": "2026-02-04 21:41:01.974465",
      "payload": {
        "nct_id": "NCT06586281",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.962791",
      "occurred_at": "2026-02-04 21:41:01.962791",
      "payload": {
        "nct_id": "NCT05004727",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.948866",
      "occurred_at": "2026-02-04 21:41:01.948866",
      "payload": {
        "nct_id": "NCT05669833",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.935401",
      "occurred_at": "2026-02-04 21:41:01.935401",
      "payload": {
        "nct_id": "NCT07255781",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.922553",
      "occurred_at": "2026-02-04 21:41:01.922553",
      "payload": {
        "nct_id": "NCT06651489",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.910764",
      "occurred_at": "2026-02-04 21:41:01.910764",
      "payload": {
        "nct_id": "NCT04929210",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.895445",
      "occurred_at": "2026-02-04 21:41:01.895445",
      "payload": {
        "nct_id": "NCT05049798",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.873450",
      "occurred_at": "2026-02-04 21:41:01.873450",
      "payload": {
        "nct_id": "NCT06663332",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.860340",
      "occurred_at": "2026-02-04 21:41:01.860340",
      "payload": {
        "nct_id": "NCT05347095",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.845069",
      "occurred_at": "2026-02-04 21:41:01.845069",
      "payload": {
        "nct_id": "NCT07141004",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.832851",
      "occurred_at": "2026-02-04 21:41:01.832851",
      "payload": {
        "nct_id": "NCT06408935",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.819365",
      "occurred_at": "2026-02-04 21:41:01.819365",
      "payload": {
        "nct_id": "NCT03451851",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.789380",
      "occurred_at": "2026-02-04 21:41:01.789380",
      "payload": {
        "nct_id": "NCT04882098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.770135",
      "occurred_at": "2026-02-04 21:41:01.770135",
      "payload": {
        "nct_id": "NCT04936308",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.293886",
      "occurred_at": "2026-02-04 21:41:01.293886",
      "payload": {
        "nct_id": "NCT04496063",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.267891",
      "occurred_at": "2026-02-04 21:41:01.267891",
      "payload": {
        "nct_id": "NCT05387031",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.241346",
      "occurred_at": "2026-02-04 21:41:01.241346",
      "payload": {
        "nct_id": "NCT02103361",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.216730",
      "occurred_at": "2026-02-04 21:41:01.216730",
      "payload": {
        "nct_id": "NCT05299931",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.204269",
      "occurred_at": "2026-02-04 21:41:01.204269",
      "payload": {
        "nct_id": "NCT03941132",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.189354",
      "occurred_at": "2026-02-04 21:41:01.189354",
      "payload": {
        "nct_id": "NCT06807593",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.175021",
      "occurred_at": "2026-02-04 21:41:01.175021",
      "payload": {
        "nct_id": "NCT05083182",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.161308",
      "occurred_at": "2026-02-04 21:41:01.161308",
      "payload": {
        "nct_id": "NCT07303686",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.148528",
      "occurred_at": "2026-02-04 21:41:01.148528",
      "payload": {
        "nct_id": "NCT07310095",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.122342",
      "occurred_at": "2026-02-04 21:41:01.122342",
      "payload": {
        "nct_id": "NCT05092269",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.098124",
      "occurred_at": "2026-02-04 21:41:01.098124",
      "payload": {
        "nct_id": "NCT04372108",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:01.074326",
      "occurred_at": "2026-02-04 21:41:01.074326",
      "payload": {
        "nct_id": "NCT07245394",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.630540",
      "occurred_at": "2026-02-04 21:41:00.630540",
      "payload": {
        "nct_id": "NCT05778097",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.616265",
      "occurred_at": "2026-02-04 21:41:00.616265",
      "payload": {
        "nct_id": "NCT03899077",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.602402",
      "occurred_at": "2026-02-04 21:41:00.602402",
      "payload": {
        "nct_id": "NCT03141671",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.584382",
      "occurred_at": "2026-02-04 21:41:00.584382",
      "payload": {
        "nct_id": "NCT04295447",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.560422",
      "occurred_at": "2026-02-04 21:41:00.560422",
      "payload": {
        "nct_id": "NCT04812366",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.545093",
      "occurred_at": "2026-02-04 21:41:00.545093",
      "payload": {
        "nct_id": "NCT03902951",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.514935",
      "occurred_at": "2026-02-04 21:41:00.514935",
      "payload": {
        "nct_id": "NCT03903835",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.497148",
      "occurred_at": "2026-02-04 21:41:00.497148",
      "payload": {
        "nct_id": "NCT02913196",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.468976",
      "occurred_at": "2026-02-04 21:41:00.468976",
      "payload": {
        "nct_id": "NCT05191680",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.455067",
      "occurred_at": "2026-02-04 21:41:00.455067",
      "payload": {
        "nct_id": "NCT06067269",
        "linked_assets": 3
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.415100",
      "occurred_at": "2026-02-04 21:41:00.415100",
      "payload": {
        "nct_id": "NCT04181203",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.391760",
      "occurred_at": "2026-02-04 21:41:00.391760",
      "payload": {
        "nct_id": "NCT06274047",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.373812",
      "occurred_at": "2026-02-04 21:41:00.373812",
      "payload": {
        "nct_id": "NCT05960578",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.347174",
      "occurred_at": "2026-02-04 21:41:00.347174",
      "payload": {
        "nct_id": "NCT07002320",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.322415",
      "occurred_at": "2026-02-04 21:41:00.322415",
      "payload": {
        "nct_id": "NCT04662580",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.308719",
      "occurred_at": "2026-02-04 21:41:00.308719",
      "payload": {
        "nct_id": "NCT05818683",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.293073",
      "occurred_at": "2026-02-04 21:41:00.293073",
      "payload": {
        "nct_id": "NCT03523442",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.271756",
      "occurred_at": "2026-02-04 21:41:00.271756",
      "payload": {
        "nct_id": "NCT05901649",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.258063",
      "occurred_at": "2026-02-04 21:41:00.258063",
      "payload": {
        "nct_id": "NCT04557059",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.227442",
      "occurred_at": "2026-02-04 21:41:00.227442",
      "payload": {
        "nct_id": "NCT05884398",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.211824",
      "occurred_at": "2026-02-04 21:41:00.211824",
      "payload": {
        "nct_id": "NCT03767244",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.195801",
      "occurred_at": "2026-02-04 21:41:00.195801",
      "payload": {
        "nct_id": "NCT04267887",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.157746",
      "occurred_at": "2026-02-04 21:41:00.157746",
      "payload": {
        "nct_id": "NCT04325828",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:41:00.141886",
      "occurred_at": "2026-02-04 21:41:00.141886",
      "payload": {
        "nct_id": "NCT04108208",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:57.535403",
      "occurred_at": "2026-02-04 21:40:57.535403",
      "payload": {
        "nct_id": "NCT04951622",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:55.764391",
      "occurred_at": "2026-02-04 21:40:55.764391",
      "payload": {
        "nct_id": "NCT05265273",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:55.749484",
      "occurred_at": "2026-02-04 21:40:55.749484",
      "payload": {
        "nct_id": "NCT06251076",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:54.851924",
      "occurred_at": "2026-02-04 21:40:54.851924",
      "payload": {
        "nct_id": "NCT05197049",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:53.488749",
      "occurred_at": "2026-02-04 21:40:53.488749",
      "payload": {
        "nct_id": "NCT05528510",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.998425",
      "occurred_at": "2026-02-04 21:40:52.998425",
      "payload": {
        "nct_id": "NCT07217587",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.527614",
      "occurred_at": "2026-02-04 21:40:52.527614",
      "payload": {
        "nct_id": "NCT03218488",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.513017",
      "occurred_at": "2026-02-04 21:40:52.513017",
      "payload": {
        "nct_id": "NCT07196748",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.496126",
      "occurred_at": "2026-02-04 21:40:52.496126",
      "payload": {
        "nct_id": "NCT05912517",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.477476",
      "occurred_at": "2026-02-04 21:40:52.477476",
      "payload": {
        "nct_id": "NCT05242471",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.448334",
      "occurred_at": "2026-02-04 21:40:52.448334",
      "payload": {
        "nct_id": "NCT05923073",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.390790",
      "occurred_at": "2026-02-04 21:40:52.390790",
      "payload": {
        "nct_id": "NCT05242484",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.352817",
      "occurred_at": "2026-02-04 21:40:52.352817",
      "payload": {
        "nct_id": "NCT07196722",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.326471",
      "occurred_at": "2026-02-04 21:40:52.326471",
      "payload": {
        "nct_id": "NCT06559306",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.309563",
      "occurred_at": "2026-02-04 21:40:52.309563",
      "payload": {
        "nct_id": "NCT07227454",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.291253",
      "occurred_at": "2026-02-04 21:40:52.291253",
      "payload": {
        "nct_id": "NCT06741969",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.274265",
      "occurred_at": "2026-02-04 21:40:52.274265",
      "payload": {
        "nct_id": "NCT06934226",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:52.258227",
      "occurred_at": "2026-02-04 21:40:52.258227",
      "payload": {
        "nct_id": "NCT06260163",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:50.838498",
      "occurred_at": "2026-02-04 21:40:50.838498",
      "payload": {
        "nct_id": "NCT04033445",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:50.798025",
      "occurred_at": "2026-02-04 21:40:50.798025",
      "payload": {
        "nct_id": "NCT03466411",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:41.567573",
      "occurred_at": "2026-02-04 21:40:41.567573",
      "payload": {
        "nct_id": "NCT07219212",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:41.553106",
      "occurred_at": "2026-02-04 21:40:41.553106",
      "payload": {
        "nct_id": "NCT04892173",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:41.165863",
      "occurred_at": "2026-02-04 21:40:41.165863",
      "payload": {
        "nct_id": "NCT07029776",
        "linked_assets": 3
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:41.150448",
      "occurred_at": "2026-02-04 21:40:41.150448",
      "payload": {
        "nct_id": "NCT06285318",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:41.136118",
      "occurred_at": "2026-02-04 21:40:41.136118",
      "payload": {
        "nct_id": "NCT06208150",
        "linked_assets": 2
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 21:40:41.115920",
      "occurred_at": "2026-02-04 21:40:41.115920",
      "payload": {
        "nct_id": "NCT05972135",
        "linked_assets": 2
      }
    },
    {
      "event_type": "pipeline_ingested",
      "created_at": "2026-02-04 21:40:37.592001",
      "occurred_at": "2026-02-04 21:40:37.592001",
      "payload": {
        "as_of_date": null,
        "pdf_url": "https://s203.q4cdn.com/636242992/files/doc_financials/2025/q4/JNJ-Pipeline-4Q25.pdf",
        "assets_seen": 41
      }
    },
    {
      "event_type": "asset_indication_removed",
      "created_at": "2026-02-04 21:40:37.589384",
      "occurred_at": "2026-02-04 21:40:37.589384",
      "payload": {
        "asset": "SIRTURO",
        "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
        "stage": "Phase 3",
        "therapeutic_area": null
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.586871",
      "occurred_at": "2026-02-04 21:40:37.586871",
      "payload": {
        "asset": "SIRTURO",
        "indication": "L e p r o s y under review by regulatory bodies.",
        "stage": "Phase 3",
        "therapeutic_area": null
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.568028",
      "occurred_at": "2026-02-04 21:40:37.568028",
      "payload": {
        "asset": "(OARS)",
        "indication": "Agitation Disorder",
        "stage": "Phase 2",
        "therapeutic_area": "Neuroscience"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.540232",
      "occurred_at": "2026-02-04 21:40:37.540232",
      "payload": {
        "asset": "(PROTOSTAR)",
        "indication": "Arthritis Hemolytic Anemia (ENERGY) Alloimmune Thrombocytopenia",
        "stage": "Registration",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.531294",
      "occurred_at": "2026-02-04 21:40:37.531294",
      "payload": {
        "asset": "of the Fetus and Newborn",
        "indication": "Colitis (QUASAR JR)",
        "stage": "Phase 2",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.518427",
      "occurred_at": "2026-02-04 21:40:37.518427",
      "payload": {
        "asset": "Subcutaneous Induction",
        "indication": "(ICONIC-PsA)",
        "stage": "Phase 2",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.498004",
      "occurred_at": "2026-02-04 21:40:37.498004",
      "payload": {
        "asset": "icotrokinra",
        "indication": "Crohn's Disease (ICONIC-CD)",
        "stage": "Phase 3",
        "therapeutic_area": "Immunology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.474045",
      "occurred_at": "2026-02-04 21:40:37.474045",
      "payload": {
        "asset": "JNJ-3413",
        "indication": "Lymphoma",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.447461",
      "occurred_at": "2026-02-04 21:40:37.447461",
      "payload": {
        "asset": "JNJ-1493",
        "indication": "Hematological",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.430673",
      "occurred_at": "2026-02-04 21:40:37.430673",
      "payload": {
        "asset": "Azacitidine",
        "indication": "Cancer (ATLAS) intravesical delivery system) Invasive Bladder Cancer BCG",
        "stage": "Registration",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.417481",
      "occurred_at": "2026-02-04 21:40:37.417481",
      "payload": {
        "asset": "TALVEY + TECVAYLI",
        "indication": "Relapsed Refractory (MonumenTAL-6)",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.398504",
      "occurred_at": "2026-02-04 21:40:37.398504",
      "payload": {
        "asset": "(amivantamab)",
        "indication": "Cancer (ORIGAMI-5)",
        "stage": "Phase 2",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_removed",
      "created_at": "2026-02-04 21:40:37.384045",
      "occurred_at": "2026-02-04 21:40:37.384045",
      "payload": {
        "asset": "RYBREVANT",
        "indication": "Frontline Non Small",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_removed",
      "created_at": "2026-02-04 21:40:37.381686",
      "occurred_at": "2026-02-04 21:40:37.381686",
      "payload": {
        "asset": "RYBREVANT",
        "indication": "Colorectal Cancer",
        "stage": "Phase 3",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.379191",
      "occurred_at": "2026-02-04 21:40:37.379191",
      "payload": {
        "asset": "RYBREVANT",
        "indication": "Head and Neck",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_removed",
      "created_at": "2026-02-04 21:40:37.362576",
      "occurred_at": "2026-02-04 21:40:37.362576",
      "payload": {
        "asset": "TECVAYLI",
        "indication": "Relapsed Refractory",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.360100",
      "occurred_at": "2026-02-04 21:40:37.360100",
      "payload": {
        "asset": "TECVAYLI",
        "indication": "Relapsed Refractory (MajesTEC-9)",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "asset_indication_added",
      "created_at": "2026-02-04 21:40:37.351432",
      "occurred_at": "2026-02-04 21:40:37.351432",
      "payload": {
        "asset": "INLEXZO (gemcitabine",
        "indication": "Non Muscle Invasive (SunRISe-3)",
        "stage": "Phase 1",
        "therapeutic_area": "Oncology"
      }
    },
    {
      "event_type": "trials_ingested",
      "created_at": "2026-02-04 20:38:50.956810",
      "occurred_at": "2026-02-04 20:38:50.956810",
      "payload": {
        "trials_seen": 254,
        "inserted": 1,
        "updated": 253,
        "status_changed": 0,
        "bad_aliases": 0
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.784045",
      "occurred_at": "2026-02-04 20:38:39.784045",
      "payload": {
        "nct_id": "NCT04883619",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.770406",
      "occurred_at": "2026-02-04 20:38:39.770406",
      "payload": {
        "nct_id": "NCT06533098",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.755272",
      "occurred_at": "2026-02-04 20:38:39.755272",
      "payload": {
        "nct_id": "NCT06449651",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.742424",
      "occurred_at": "2026-02-04 20:38:39.742424",
      "payload": {
        "nct_id": "NCT05379634",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:39.728884",
      "occurred_at": "2026-02-04 20:38:39.728884",
      "payload": {
        "nct_id": "NCT05327114",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:38.520178",
      "occurred_at": "2026-02-04 20:38:38.520178",
      "payload": {
        "nct_id": "NCT06878404",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:38.505245",
      "occurred_at": "2026-02-04 20:38:38.505245",
      "payload": {
        "nct_id": "NCT06807424",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.984741",
      "occurred_at": "2026-02-04 20:38:36.984741",
      "payload": {
        "nct_id": "NCT03767075",
        "linked_assets": 1
      }
    },
    {
      "event_type": "trial_assets_linked",
      "created_at": "2026-02-04 20:38:36.959497",
      "occurred_at": "2026-02-04 20:38:36.959497",
      "payload": {
        "nct_id": "NCT06632236",
        "linked_assets": 1
      }
    }
  ],
  "trials": [
    {
      "nct_id": "NCT04083976",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-04",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04119050",
      "overall_status": "RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "nipocalimab"
      ]
    },
    {
      "nct_id": "NCT04538664",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "(amivantamab)"
      ]
    },
    {
      "nct_id": "NCT05663866",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "(amivantamab)"
      ]
    },
    {
      "nct_id": "NCT04487080",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "(amivantamab)"
      ]
    },
    {
      "nct_id": "NCT04181827",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04882098",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT04936308",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT04325828",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "ERLEADA"
      ]
    },
    {
      "nct_id": "NCT04108208",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE4",
      "last_update_posted": "2026-02-04",
      "linked_assets": [
        "ERLEADA"
      ]
    },
    {
      "nct_id": "NCT04113018",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-03",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06066346",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-02-03",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05388669",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "(amivantamab)"
      ]
    },
    {
      "nct_id": "NCT03390504",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03462719",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03901963",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06266663",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03596645",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03451851",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT04033445",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT03466411",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2,PHASE3",
      "last_update_posted": "2026-02-02",
      "linked_assets": [
        "STELARA",
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT03301220",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-30",
      "linked_assets": []
    },
    {
      "nct_id": "NCT02365597",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-30",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03881098",
      "overall_status": "RECRUITING",
      "phase": "NA",
      "last_update_posted": "2026-01-29",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06319820",
      "overall_status": "RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-27",
      "linked_assets": [
        "INLEXZO (gemcitabine"
      ]
    },
    {
      "nct_id": "NCT04557098",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-27",
      "linked_assets": [
        "TECVAYLI"
      ]
    },
    {
      "nct_id": "NCT05421663",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-27",
      "linked_assets": [
        "JNJ-1900",
        "autoleucel"
      ]
    },
    {
      "nct_id": "NCT05289687",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-26",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06193863",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-23",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07245394",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-23",
      "linked_assets": [
        "TREMFYA"
      ]
    },
    {
      "nct_id": "NCT05316155",
      "overall_status": "RECRUITING",
      "phase": "PHASE1,PHASE2",
      "last_update_posted": "2026-01-22",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05601973",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-21",
      "linked_assets": [
        "(amivantamab)"
      ]
    },
    {
      "nct_id": "NCT05900388",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-21",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04933539",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03652064",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06220604",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-20",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04267887",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": [
        "ERLEADA",
        "actorXla"
      ]
    },
    {
      "nct_id": "NCT05972135",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-20",
      "linked_assets": [
        "TALVEY + TECVAYLI",
        "TECVAYLI"
      ]
    },
    {
      "nct_id": "NCT07194070",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT02354014",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": [
        "RYBREVANT"
      ]
    },
    {
      "nct_id": "NCT06768489",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06604715",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05652335",
      "overall_status": "RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05455320",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT07266441",
      "overall_status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05050097",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT06500884",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT04634552",
      "overall_status": "RECRUITING",
      "phase": "PHASE2",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT05160584",
      "overall_status": "RECRUITING",
      "phase": null,
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    },
    {
      "nct_id": "NCT03399799",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "last_update_posted": "2026-01-16",
      "linked_assets": []
    }
  ]
}